de Barra Mícheál, Scott Claire L, Scott Neil W, Johnston Marie, de Bruin Marijn, Nkansah Nancy, Bond Christine M, Matheson Catriona I, Rackow Pamela, Williams A Jess, Watson Margaret C
Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
Cochrane Database Syst Rev. 2018 Sep 4;9(9):CD013102. doi: 10.1002/14651858.CD013102.
This review focuses on non-dispensing services from pharmacists, i.e. pharmacists in community, primary or ambulatory-care settings, to non-hospitalised patients, and is an update of a previously-published Cochrane Review.
To examine the effect of pharmacists' non-dispensing services on non-hospitalised patient outcomes.
We searched CENTRAL, MEDLINE, Embase, two other databases and two trial registers in March 2015, together with reference checking and contact with study authors to identify additional studies. We included non-English language publications. We ran top-up searches in January 2018 and have added potentially eligible studies to 'Studies awaiting classification'.
Randomised trials of pharmacist services compared with the delivery of usual care or equivalent/similar services with the same objective delivered by other health professionals.
We used standard methodological procedures of Cochrane and the Effective Practice and Organisation of Care Group. Two review authors independently checked studies for inclusion, extracted data and assessed risks of bias. We evaluated the overall certainty of evidence using GRADE.
We included 116 trials comprising 111 trials (39,729 participants) comparing pharmacist interventions with usual care and five trials (2122 participants) comparing pharmacist services with services from other healthcare professionals. Of the 116 trials, 76 were included in meta-analyses. The 40 remaining trials were not included in the meta-analyses because they each reported unique outcome measures which could not be combined. Most trials targeted chronic conditions and were conducted in a range of settings, mostly community pharmacies and hospital outpatient clinics, and were mainly but not exclusively conducted in high-income countries. Most trials had a low risk of reporting bias and about 25%-30% were at high risk of bias for performance, detection, and attrition. Selection bias was unclear for about half of the included studies.Compared with usual care, we are uncertain whether pharmacist services reduce the percentage of patients outside the glycated haemoglobin target range (5 trials, N = 558, odds ratio (OR) 0.29, 95% confidence interval (CI) 0.04 to 2.22; very low-certainty evidence). Pharmacist services may reduce the percentage of patients whose blood pressure is outside the target range (18 trials, N = 4107, OR 0.40, 95% CI 0.29 to 0.55; low-certainty evidence) and probably lead to little or no difference in hospital attendance or admissions (14 trials, N = 3631, OR 0.85, 95% CI 0.65 to 1.11; moderate-certainty evidence). Pharmacist services may make little or no difference to adverse drug effects (3 trials, N = 590, OR 1.65, 95% CI 0.84 to 3.24) and may slightly improve physical functioning (7 trials, N = 1329, mean difference (MD) 5.84, 95% CI 1.21 to 10.48; low-certainty evidence). Pharmacist services may make little or no difference to mortality (9 trials, N = 1980, OR 0.79, 95% CI 0.56 to 1.12, low-certaintly evidence).Of the five studies that compared services delivered by pharmacists with other health professionals, no studies evaluated the impact of the intervention on the percentage of patients outside blood pressure or glycated haemoglobin target range, hospital attendance and admission, adverse drug effects, or physical functioning.
AUTHORS' CONCLUSIONS: The results demonstrate that pharmacist services have varying effects on patient outcomes compared with usual care. We found no studies comparing services delivered by pharmacists with other healthcare professionals that evaluated the impact of the intervention on the six main outcome measures. The results need to be interpreted cautiously because there was major heterogeneity in study populations, types of interventions delivered and reported outcomes.There was considerable heterogeneity within many of the meta-analyses, as well as considerable variation in the risks of bias.
本综述聚焦于药剂师提供的非配药服务,即社区、基层或门诊护理机构中的药剂师为非住院患者提供的服务,是对之前发表的Cochrane综述的更新。
探讨药剂师的非配药服务对非住院患者结局的影响。
我们于2015年3月检索了Cochrane中心对照试验注册库(CENTRAL)、医学期刊数据库(MEDLINE)、荷兰医学文摘数据库(Embase)以及另外两个数据库和两个试验注册库,并通过参考文献核对及与研究作者联系以识别其他研究。我们纳入了非英语语言出版物。我们于2018年1月进行了补充检索,并将潜在符合条件的研究添加到“待分类研究”中。
将药剂师服务与常规护理或其他卫生专业人员提供的具有相同目标的等效/类似服务进行比较的随机试验。
我们采用了Cochrane协作网以及有效实践与医疗组织小组的标准方法程序。两名综述作者独立检查研究是否符合纳入标准、提取数据并评估偏倚风险。我们使用GRADE评估证据的总体确定性。
我们纳入了116项试验,其中111项试验(39729名参与者)比较了药剂师干预与常规护理,5项试验(2122名参与者)比较了药剂师服务与其他医疗保健专业人员的服务。在这116项试验中,76项被纳入荟萃分析。其余40项试验未纳入荟萃分析,因为它们各自报告的独特结局指标无法合并。大多数试验针对慢性病,在一系列场所进行,主要是社区药房和医院门诊诊所,并且主要但不限于在高收入国家开展。大多数试验报告偏倚风险较低,约25%-30%在实施、检测和失访方面存在高偏倚风险。约一半纳入研究的选择偏倚尚不清楚。与常规护理相比,我们不确定药剂师服务是否能降低糖化血红蛋白未达目标范围的患者百分比(5项试验,N = 558,比值比(OR)0.29,95%置信区间(CI)0.04至2.22;极低确定性证据)。药剂师服务可能降低血压未达目标范围的患者百分比(18项试验,N = 4107,OR 0.40,95% CI 0.29至0.55;低确定性证据),并且可能在就诊或住院方面导致几乎没有差异(14项试验,N = 3631,OR 0.85,95% CI 0.65至1.11;中等确定性证据)。药剂师服务可能对药物不良反应几乎没有影响(3项试验,N = 590,OR 1.